BAM
FOLD

Blueshift Asset Management’s Amicus Therapeutics FOLD Stock Holding History

Blueshift Asset Management’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-89,766
Closed -$857K – 982
2021
Q3 		$857K Buy
89,766
+68,863
+329% +$704K 0.05% 452
2021
Q2 		$202K Buy
+20,903
New +$204K 0.01% 843
2021
Q1 		– Sell
-18,032
Closed -$416K – 923
2020
Q4 		$416K Buy
+18,032
New +$369K 0.05% 455
2020
Q1 		– Sell
-22,717
Closed -$221K – 375
2019
Q4 		$221K Buy
22,717
+10,539
+87% +$96.5K 0.03% 695
2019
Q3 		$98K Buy
+12,178
New +$132K 0.01% 678

Other funds holding FOLD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Blueshift Asset Management's FOLD Position: Q4 2021 in Review

Blueshift Asset Management sold out of Amicus Therapeutics (FOLD) in Q4 2021, closing a stake of 89,766 shares — an estimated $857K sold.

Blueshift Asset Management first reported a position in FOLD in Q3 2019 and held it in 5 quarters. The position peaked at $857K in Q3 2021. 224 funds tracked by Wall St. Rank hold FOLD as of Q4 2021.

  • Blueshift Asset Management reported no remaining Amicus Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Blueshift Asset Management sold 89,766 Amicus Therapeutics shares in Q4 2021, an estimated $857K.
  • Blueshift Asset Management first reported a position in Amicus Therapeutics in Q3 2019 and held it in 5 quarters.
  • Blueshift Asset Management's Amicus Therapeutics position peaked at $857K in Q3 2021.
  • 224 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2021.

Based on Blueshift Asset Management's 13F filing for Q4 2021, filed 11 Feb 2022.